Drug-eluting stents

descriptionPublicationkeyboard_double_arrow_right Article 22 May 2007 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 176, pages 1,611-1,611 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )

Authors: E Liana, Falcone; Navdeep, Tangri;

doi: 10.1503/cmaj.1070022

pmid: 17515590

pmc: PMC1867843

Drug-eluting stents

- Summary
- Subjects
- Metrics

Abstract

In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the study

Keywords

Canada, Drug Delivery Systems, Ticlopidine, Cost-Benefit Analysis, Humans, Stents, Coronary Artery Disease, Platelet Aggregation Inhibitors, Clopidogrel

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average